✦ LIBER ✦

Targeting EGFR and HER-2 Receptor Tyrosine Kinases for Cancer Drug Discovery and Development

✍ Scribed by Shantaram Kamath; John K. Buolamwini

Publisher: John Wiley and Sons
Year: 2006
Weight: 8 KB
Volume: 37
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200646272

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting EGFR and HER-2 receptor tyrosi

Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development

✍ Shantaram Kamath; John K. Buolamwini 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor signaling are gaining interest. The erbB receptor family belongs to the type I, the receptor tyrosine kinases class, an

Receptor tyrosine kinases in sinonasal u

Receptor tyrosine kinases in sinonasal undifferentiated carcinomas—Evaluation for EGFR, c-KIT, and HER2/neu expression

✍ Rebecca D. Chernock; Arie Perry; John D. Pfeifer; Joseph A. Holden; James S. Lew 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

## Abstract ## __Background.__ Our objective was to identify the expression of epidermal growth factor receptor (EGFR), c‐KIT (CD117), and HER2/neu in sinonasal undifferentiated carcinoma (SNUC). ## __Methods.__ Immunohistochemistry for c‐KIT (CD117), EGFR, and HER2/neu was performed on paraffin

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

P2 purinergic receptors on osteoblasts a

P2 purinergic receptors on osteoblasts and osteoclasts: Potential targets for drug development

✍ S. Jeffrey Dixon; Stephen M. Sims 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

Extracellular nucleotides like ATP bind to cell surface receptors (P2 purinergic receptors) in many tissues. P2X receptor subtypes are intrinsic ion channels that mediate depolarization and influx of Ca 2+ , whereas the P2Y receptor subtypes couple through G proteins to activation of phospholipase C

The dual EGFR/HER-2 tyrosine kinase inhi

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

✍ Melissa J. LaBonte; Philipp C. Manegold; Peter M. Wilson; Will Fazzone; Stan G. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 482 KB

## Abstract Members of the human epidermal receptor (HER) family are frequently associated with aggressive disease and poor prognosis in multiple malignancies. Lapatinib is a dual tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) and HER‐2. This study evaluated the the

ChemInform Abstract: Discovery and Devel

ChemInform Abstract: Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases

✍ Philip S. Low; Walter A. Henne; Derek D. Doorneweerd 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 15 KB 👁 1 views